Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 760 participants.
Also called NCT01870804
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 760 participants
- Sponsor
- Centro Cardiopatici Toscani
- Registry
-
NCT01870804
-
- Other papers using this trial's data
- A Prospective, Randomized, Open-Label Trial of Atorvastatin versus Rosuvastatin in the Prevention of Contrast-Induced Acute Kidney Injury, Worsened Renal Function at 30 Days, and Clinical Events After Acute Coronary Angiography: the PRATO-ACS-2 Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Italy
- Registry status
- Completed
Technical summary
Registry record NCT01870804. Randomized; double masking; primary purpose prevention. Start 2013-05 (registry gives no type); primary completion 2016-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)
- Acronym
- PRATO-ACS-2
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Atorvastatin
- Lead sponsor
- Centro Cardiopatici Toscani
Record details
- Record id
cardio:ct-nct01870804- Content hash
472f58b03134dd6b597424b483d2f6c202e19ffb4e2b4df4d5e6891b099ab9d3